{
  "guideline": {
    "id": "PA166265162",
    "name": "Annotation of DPWG Guideline for carbamazepine and HLA-B",
    "source": "DPWG",
    "version": 8,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166265162",
    "relatedChemicals": [
      {
        "id": "PA448785",
        "name": "carbamazepine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA35056",
        "name": "major histocompatibility complex, class I, B",
        "symbol": "HLA-B"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166299115",
      "name": "Recommendation PA166299115",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448785",
          "name": "carbamazepine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061478,
        "html": "<ul>\n<li>Choose an alternative if possible. Phenytoin, lamotrigine and oxcarbazepine also pose an increased risk of SJS/TEN in these patients, but the final risk is 10-fold lower for these medicines than for carbamazepine. Furthermore, in the case of oxcarbazepine, the most severe forms (SJS/TEN overlap and TEN) have not been observed.</li>\n</ul>\n"
      },
      "implications": [
        "Patients with this genetic variation have a severely increased risk of experiencing the life-threatening cutaneous adverse event Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). The risk of carbamazepine-induced SJS/TEN in these patients is 1.8-3.4%."
      ],
      "lookupKey": {
        "HLA-B": "*15:02 positive"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299113",
      "name": "Recommendation PA166299113",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448785",
          "name": "carbamazepine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061476,
        "html": "<ul>\n<li>\n<p>Carefully weigh the risk of SJS/TEN against the benefits</p>\n</li>\n<li>\n<p>If an alternative is an option, choose an alternative</p>\n</li>\n</ul>\n"
      },
      "implications": [
        "Patients with this genetic variation have an increased risk of experiencing the life-threatening cutaneous adverse event Stevens-Johnson syndrome/toxic epidermal necrolysis\n(SJS/TEN). The risk of carbamazepine-induced SJS/TEN in patients with the HLA-B*1502 allele, which carries a 4.6-6.6 times higher risk than the HLA-B*1511 allele, is 1.8- 3.4%. This would equate to a risk of carbamazepine-induced SJS/TEN in these patients of 0.27-0.73%."
      ],
      "lookupKey": {
        "HLA-B": "*15:11 positive"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299116",
      "name": "Recommendation PA166299116",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448785",
          "name": "carbamazepine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061479,
        "html": "<p>The guideline does not provide a recommendation for carbamazepine in patients with both HLA-B*15:02 and HLA-B*15:11 alleles or positive for both HLA-B*15:02 and HLA-B*15:11 tests.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of the presence of both HLA-B*15:02 and HLA-B*15:11 alleles on carbamazepine."
      ],
      "lookupKey": {
        "HLA-B": "1511 and 1502"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [],
  "version": "2024-03-25-16-13"
}